Hemophilia - Drug Pipeline Analysis and Market Forecasts to 2016

Pharmaceutical and healthcare report, “Hemophilia - Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global hemophilia market.

Online PR News – 22-May-2010 – – Pharmaceutical and healthcare report, “Hemophilia - Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData’s analysis suggests that the global hemophilia market was valued at $6.5 billion in 2009. This slow growth is primarily attributed to a low diagnosis rate and the high price of therapy. The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX from Baxter Laboratories. BeneFIX is a clotting factor IX.


The scope of the report includes:

Annualized global hemophilia market revenues data from 2001 to 2009, forecast for seven years to 2016.
Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
Pipeline analysis data providing a split across different phases by the mechanism of action being developed and the emerging trends. The key classes of mechanism of action include substitution of coagulation factor VIII, increasing clotting factor VIII, plasma-derived FVIII.
Analysis of the current and future market competition in the global hemophilia market. The key market players covered are PTC Therapeutics, Recoly N.V., Novo Nordisk.
Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global haemophilia market.
Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global haemophilia market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
What’s the next big thing in the global haemophilia market landscape? - Identify, understand and capitalize.

For more information on the report, kindly visit :